J Intellect Disabil Res
October 2023
Background: Intellectual disability (ID) is often associated with delays in emotional development (ED). The Scale of Emotional Development - Short (SED-S) was developed to assess the level of ED and to adapt treatment and care accordingly.
Methods: In a sample of 724 adults from five study sites in three countries, a confirmatory factor analysis with a one-factor model was conducted on the entire dataset as well as in different subgroups.
A large interview study, evolved from the clinical research project SYMPA-ID (Systemic Methods in Acute Psychiatry for People with Intellectual Disability), focused on adults with cognitive impairment and mental disorder who lived in a residential home and were in need of intensive psychiatric treatment. With the objective of analysing the interactions between the patients and their carers as well as the cooperations within the multi-carer system, both patients with mild to severe ID and their carers (relatives, legal guardians, professional carers of residential group homes as well as in- and outpatient psychiatric services) were surveyed several times between 2015 and 2018. Qualitative Data Analysis of 188 interviews with 67 participants resulted in a collection of 43 strategies concerning both attitudes and activities to prevent or cope with aggressive incidents.
View Article and Find Full Text PDFZ Kinder Jugendpsychiatr Psychother
March 2017
Objective: The study describes the burden of psychosocial risks of mental illnesses and the ways in which children and adolescents with fragile X syndrome (FRX) can be treated.
Method: Data from a sample of 34 patients with FRX younger than 18 years stemming from a prospective multicenter (n = 11) registry study (EXPLAIN) were analyzed with regard to psychosocial burden and Treatment.
Results: One third of all participants reported having relatives who suffer from FRX.
Background: As data on the phenotype, characteristics and management of patients with Fragile X Syndrome (FXS) are limited, we aimed to collect such data in Germany in experienced centres involved in the treatment of such patients.
Methods: EXPLAIN-FXS is a prospective observational (non-interventional) study (registry) performed between April 2013 and January 2016 at 18 sites in Germany. Requirements for patient participation included confirmed diagnosis of FXS by genetic testing (>200 CGG repeats) and written informed consent.